Condition-Specific Health
Rivus Pharma's Oral GLP-1 Candidate Shows Muscle-Preserving Effects in Preclinical Data
As GLP-1 weight-loss agents reshape the metabolic health market, lean-mass retention emerges as a key functional differ…
Condition-Specific Health 100 stories
Condition-Specific Health
CogniHoney's Cognitive Claims Face Scrutiny Amid Safety Questions
As honey-matrix delivery formats gain shelf space in the nootropic category, regulators and consumers alike are pressin…
Condition-Specific Health
Teva AUSTEDO Data Shows QoL Gains in Huntington's Chorea
Findings from the first decentralized, real-world HD chorea study surface patient- and caregiver-reported outcomes — a …
Condition-Specific Health
Oliv18 Olive Polyphenol Supplement Targets Cardio, Antioxidant Markets
Olive polyphenols are gaining formulation traction as dual-certification positioning signals cleaner-label credibility …
Condition-Specific Health
Anti-TLR4 Monoclonal Antibody Shows Promise in Acute Kidney Injury
TLR4 pathway modulation is drawing renewed attention as a therapeutic target in immuno-inflammatory conditions — with i…
Condition-Specific Health
IV Ketamine Outperforms Nasal Esketamine in Real-World MDD Data
Yale and Osmind researchers bring peer-reviewed real-world data to the ketamine therapy debate, with implications for c…
Condition-Specific Health
CREXONT Levodopa Data: What Formulators Should Know
Extended-release carbidopa/levodopa advances in Phase 4 — a signal for the broader controlled-release delivery science …
Condition-Specific Health
Lomitapide EU Approval Expands to Pediatric Rare Lipid Disorder
The EC label expansion targets an ultra-rare genetic LDL disorder — a reminder of how orphan-drug pipelines intersect w…
Condition-Specific Health
Orelabrutinib BTK Inhibitor Posts Safety Data in SLE Phase IIb
Data presented at EULAR 2026 add to the growing clinical record for targeted immunology compounds with potential nutrac…
![[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - Report by Zion Market Research (ZMR)](https://functional.news/public/functional/uploads/non-invasive-glucose-monitoring-market-eyes-25-6-cagr-through-2034-card.jpg)
Condition-Specific Health
Non-Invasive Glucose Monitoring Market Eyes 25.6% CAGR Through 2034
A tenfold market expansion over ten years is reshaping how brands position glycemic-support ingredients and finished fo…
Condition-Specific Health
Nervous System-Centered Recovery Model Gains Traction in Arizona
Forward-Facing® Accelerated Recovery positions autonomic nervous system modulation at the center of residential addicti…
Condition-Specific Health
MindBio Intox AI Detects Impairment via Voice Analytics
As employers expand functional wellness protocols, AI-driven impairment screening tools are entering the occupational h…